Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort

Infection

Volumn 36, Issue 4, 2008, Pages 358-361

  Righi, E ^a   Beltrame, A ^a   Bassetti, M ^a   Lindstrom, V ^a   Mazzarello, G ^a   Dentone, C ^a   Di Biagio, A ^a   Ratto, S ^a   Viscoli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABUSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MENTAL DISEASE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COHORT STUDIES; DEMOGRAPHY; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 50649118317     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7319-5     Document Type: Article

References (26)

1. Rockstroh J, Konopnicki D, Soriano V, Kirk O, Antunes F, Knysz B: Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART. In: 11th conference on retroviruses and opportunistic infections, San Francisco 2004 (Abstract 799).
2. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D: Treatment of chronic hepatitis C infection in injecting drug users. Hepathology 2001; 34: 188-193.
3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
4. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247.
5. Bonacini MJ: Diagnosis and management of cirrhosis in coinfected patients. Acquir Immune Defic Syndr 2007; 1: S38-S46.
6. Piroth L, Duong M, Quantin C, Abrahamowicz M, Michardiere R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavanet P: Does hepatitis C virus coinfection accelerate clinical and immunological evolution of HIV-infected patients?. AIDS 1998; 12: 381-388.
7. Macias J, Melguizo I, Fernandez-Rivera FJ, García-García A, Mira JA, Ramos AJ, Rivera JM, Pineda JA: Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21: 775-781.
8. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
9. Torriani FJ, Chung RT: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
10. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, AIDS Clinical Trials Group A5071 Study Team: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New Engl J Med 2004; 351: 451-459.
11. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292 (23): 2839-2848.
12. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N, Hatzakis A, Pol S, Rockstroh J: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 2007; 21(9):1073-1089.
13. Sax PE: Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat. AIDS Clin Care 2005; 17(10):97-98.
14. Shire NJ, Welge JA, Sherman KE: Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007; 14(4):239-248.
15. Pawlotsky JM: HCV genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003; 7: 45-66.
16. Databases I.Co.Na and Master.
17. Puoti M, Spinetti A, Ghezzi A: Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24(3):211-217.
18. Soriano V, Nunez M, Camino N, Maida I, Barreiro P, Romero M, Martin-Carbonero L, Garcia-Samaniego J, Gonzalez-Lahoz J: Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9(4):505-509.
19. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13(10):683-689.
20. Moreno A: Pegyilated interferon alpha-2b plus ribavirina for the treatment of chronic hepatitis C in HIV infected patients. AIDS 2004; 18: 67-73.
21. McGovern BJH: Hepatitis C in the HIV-infected patient. Acquir Immune Defic Syndr 2007; 1: S47-S56.
22. Puoti M, Zanini B, Quinzan GP, Ravasio L, Paraninfo G, Santantonio T: A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. J Hepatol 2004; 41(2):312-318.
23. Fried M, Shiffman M, Reddy R: Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
24. Ballestreros A, Franco S, Fuster D, Planas R, Martinez M: Early HCV dynamic on peginterferon and ribavirin in HIV/HCV coinfection: indications for the investigation of new treatment approaches. AIDS 2004; 18: 67-73.
25. Landau A, Batisse D, Picketty C: Long-term efficacy of combination therapy with interferon alpha-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15: 2149-2155.
26. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P. Italian Co-infection Study (ICOS) Group: Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005; 10(2):309-317.